The discovery in 2001 by Hoffman and colleagues on genetic alterations in the NLRP3 gene as a prime source for the set of autosomal dominantly inherited inflammatory diseases, combinedly known as cryopyrin associated periodic syndrome (CAPS), was a breakthrough in the clinical execution of these diseases [1]. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.